None listed
Conditions
Brief summary
The researchers will see people with CH, or who may have CH. For people who may have CH, the researchers will organise testing to confirm the condition after providing counselling. People with CH who agree to participate in the study will also have monitoring of their CH, assessment of the risk of heart diseases, and personalised support. The researchers will also measure people’s understanding of CH and how they feel after learning about CH. Researchers will then record the relevant information from people with CH in a central database over time to track long-term outcomes. The information collected from the study will help create a blueprint for doctors to provide care for people with CH in the future, and guide further research into CH.
Interventions
After providing written informed consent, participants will be asked to:
Provide peripheral blood samples for research purposes at screening (where required), Week 0, and then either annually, or biennially, thereafter alongside routine care samples.
Complete 3 participant surveys during the study - Custom CH survey, the K6 scale and B-IPQ. The study surveys, questionnaires are paper based and the completion of these and review of information alongside them will take approximately 20 minutes
After providing written informed consent, participants will be asked to: Provide peripheral blood samples for research purposes at screening (where required), Week 0, and then either annually, or biennially, thereafter alongside routine care samples. Complete 3 participant surveys during the study - Custom CH survey, the K6 scale and B-IPQ. The study surveys, questionnaires are paper based and the completion of these and review of information alongside them will take approximately 20 minutes to read and fill out. These will be completed at screening, Week 6 and then either annually, or biennially, thereafter Participant health information and symptom directed physical exams will used to identify CH associated complications throughout the study at Week 0 and then either annually, or biennially, thereafter The period participants will be on this study will be approximately 5 years with study-related activities lining up with other clinical care and follow up.
Sponsors
Australian National University
Eligibility
Sex/Gender
All
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged 55 years and above 2. Confirmed CH or possible CH, with possible CH defined by: a. Persistent, non-severe cytopenia, characterised by one or more of the following, present on at least 2 occasions, at least 4 months apart: i. Absolute neutrophil count (ANC) < 1.8 x 10 9/L ii. Haemoglobin (Hb) < 115 g/L in females, < 135 g/L in males iii. Platelet count < 150 x 109/L 3. Provision of written informed consent prior to any study-related assessments or procedures being carried out.
Exclusion criteria
1. Severe cytopenia as defined by one or more of the following: a. ANC < 0.5 x10 9/L b. Hb < 80 g/L c. Platelet count < 50 x 10 9/L 2. Multilineage cytopenias: a. Marked trilineage cytopenia with all the following present: i. ANC < 1.0 x 109/L AND ii. Hb < 110 g/L AND iii. Platelet count < 100 x 109/L b. Marked bilineage cytopenia, with two or more of the following present: i. ANC < 1.0 x 109/L ii. Hb < 110 g/L iii. Platelet count < 100 x 109/L 3. Cytopenia attributed to other causes, including: a. Child-Pugh C cirrhosis b. Myelosuppressive medications c. Haematinic deficiencies d. Haematological malignancies e. Haemolytic anaemia
Outcome results
None listed